Molecules, Vol. 25, Pages 3138: Aptamers in Non-Small Cell Lung Cancer Treatment
Molecules, Vol. 25, Pages 3138: Aptamers in Non-Small Cell Lung Cancer Treatment
Molecules doi: 10.3390/molecules25143138
Authors:
Irena Wieleba
Kamila Wojas-Krawczyk
Paweł Krawczyk
Aptamers are short, single-stranded oligonucleotides which are capable of specifically binding to single molecules and cellular structures. Aptamers are also known as “chemical antibodies”. Compared to monoclonal antibodies, they are characterized by higher reaction specificity, lower molecular weight, lower production costs, and lower variability in the production stage. Aptamer research has been extended during the past twenty years, but only Macugen® has been accepted by the Food and Drug Administration (FDA) to date, and few aptamers have been examined in clinical trials. In vitro studies with aptamers have shown that they may take part in the regulation of cancer progression, angiogenesis, and metastasis processes. In this article, we focus on the potential use of aptamers in non-small cell lung cancer treatment.
Source: Molecules - Category: Chemistry Authors: Irena Wieleba Kamila Wojas-Krawczyk Pawe ł Krawczyk Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Clinical Trials | Food and Drug Administration (FDA) | Lung Cancer | Non-Small Cell Lung Cancer | Study